Categories: News

Inogen to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

GOLETA, Calif.–(BUSINESS WIRE)–Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report fourth quarter and full year 2023 financial results after the market closes on Tuesday, February 27, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.


Individuals interested in listening to the conference call may do so by dialing:

US domestic callers (877) 841-3961

Non-US callers (201) 689-8589

Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen’s website at: http://investor.inogen.com/. This webcast will also be archived on the website for 6 months.

A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through March 5, 2024. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13743411.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

About Inogen

Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its oxygen therapy products widely available allowing patients the chance to remain ambulatory while managing the impact of their disease.

For more information, please visit www.inogen.com.

Contacts

ir@inogen.net

Staff

Recent Posts

PreveCeutical Closes Final Tranche of Up-Sized Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - May 22, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)…

33 minutes ago

Announcing the 2025 St. Baldrick’s Summer Fellows: Investing in the Future of Childhood Cancer Research

Los Angeles, California--(Newsfile Corp. - May 22, 2025) - The St. Baldrick's Foundation, the largest…

3 hours ago

Clymb Clinical Introduces TFL Viewer: A Cutting-Edge Platform for Collaborative Clinical Trial Reporting

BURLINGTON, Mass., May 22, 2025 /PRNewswire/ -- Clymb Clinical is proud to announce the launch…

4 hours ago

AbbaDox Named a Top South Florida Workplace for Third Year in a Row

A people-first culture continues to earn national and regional recognition BOCA RATON, Fla., May 22,…

4 hours ago

Rodan + Fields Unveils “Love What You See” – A Campaign Honoring Personal Skincare Journeys

New purpose-driven brand campaign highlights the science behind R+F's skincare and the visible results it…

4 hours ago